Bio-gene Technology Ltd. · ASX:BGT
Bio-gene Technology — Shareholder Meeting (November 2020)
18 slides from Bio-gene Technology's shareholder meeting presentation, Nov 26, 2020
Slide 1: Enabling the Next Generation of Novel Insecticides
ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES BIO-GENE For personal use only TECHNOLOGY LIMITED 26 NOVEMBER 2020 Annual General Meeting PRESENTED BY Robert Klupacs NON-EXECUTIVE DIRECTOR Richard Jagger CEO
Slide 2: Annual General Meeting - Robert Klupacs
For personal use only ANNUAL GENERAL MEETING BIO-GENE TECHNOLOGY LIMITED Robert Klupacs NON-EXECUTIVE DIRECTOR 2
Slide 3: Our Strategic Objective
2020 ANNUAL GENERAL MEETING OUR STRATEGIC Generate multiple revenue streams from technology For personal use only licensing fees, milestone payments and royalties by OBJECTIVE Securing & owning active ingredient product registrations Working with strong commercial partners on product development; ma
Slide 4: Positive Progress in Key Areas
2020 ANNUAL GENERAL MEETING POSITIVE Important toxicology & Advancing our Flavocide Additional interest from For personal use only efficacy data that manufacturing process companies entering into PROGRESS IN strengthens regulatory package and reinforces from lab-bench to pilot industrial scale Mater
Slide 5: Capital Management
2020 ANNUAL GENERAL MEETING CAPITAL For personal use only MANAGEMENT Funding in place to Potential for expanded proceed with key program development agreement trials and activities to be concluded within that period Strong ongoing focus on funds being invested so as to achieve maximum progress again
Slide 6: Building Future Value
2020 ANNUAL GENERAL MEETING BUILDING For personal use only FUTURE VALUE Commitment to lift level of Opportunity to Board focused on investor engagement communicate confidence supporting management and value proposition to achieve positive more clearly progress over next 12 months and beyond 6
Slide 7: Remuneration Report
2020 ANNUAL GENERAL MEETING REMUNERATION For personal use only REPORT Commitment to reassess approach to remuneration structure and incentives Future proposals will benefit from direct consultation with shareholders 7
Slide 8: Board Structure and Renewal
2020 ANNUAL GENERAL MEETING BOARD For personal use only STRUCTURE AND RENEWAL Committed to ensuring right mix Discussions & due diligence of talent, experience and skills to underway with several support Bio-Gene’s strategic potential Board member objectives and on-going needs candidates – this is a
Slide 9: Annual General Meeting - Richard Jagger, CEO
For personal use only ANNUAL GENERAL MEETING BIO-GENE TECHNOLOGY LIMITED Richard Jagger CEO 9
Slide 10: Important Positive Progress Over the Past Months
2020 ANNUAL GENERAL MEETING IMPORTANT POSITIVE PROGRESS OVER THE PAST 12 MONTHS For personal use only Demonstrated effectiveness of Further studies have been Successful scale-up of our Additional MTAs signed with Flavocide against stored grain completed that help articulate Flavocide manufacturing c
Slide 11: Additional Interest in Our Technology
2020 ANNUAL GENERAL MEETING ADDITIONAL For personal use only INTEREST IN OUR TECHNOLOGY Crop Protection Consumer Products MTAs in place with companies that cover a range of geographic markets and span our four key Public Grain end-use markets Health Storage These agreements cover preliminary assessm
Slide 12: Stored Grain Pest Evaluation Program
2020 ANNUAL GENERAL MEETING STORED GRAIN For personal use only PEST EVALUATION Stage 1 identified optimum product combination for control of the major Testing also identified minimum application rates to be effective against PROGRAM pest, the Lesser grain borer resistant pests AUSTRALIA Stage 2 test
Slide 13: Mosquito Evaluation Program
2020 ANNUAL GENERAL MEETING MOSQUITO For personal use only EVALUATION Agreement entered into in April of this year Testing commenced in September to assess various solvents as base PROGRAM carriers – expected to take 4-5 months THE AMERICAS Evaluating Flavocide and Qcide for Expect to then test lead
Slide 14: Working Towards Our First Commercial Partnership Agreement
2020 ANNUAL GENERAL MEETING WORKING TOWARDS OUR The completeness and strength of our data is For personal use only FIRST COMMERCIAL fundamental to negotiating better PARTNERSHIP AGREEMENT financial and commercial terms in any such agreements As we progress the testing Our objective is to conclude an
Slide 15: A Relentless Focus on Building the Value of Our Technology
2020 ANNUAL GENERAL MEETING A RELENTLESS FOCUS ON For personal use only BUILDING THE VALUE OF Safety OUR TECHNOLOGY Generating strong data that demonstrate Efficacy Manufacturing / production capabilities 15
Slide 16: Key Priorities for the Next Months
2020 ANNUAL GENERAL MEETING KEY PRIORITIES FOR THE NEXT 12 MONTHS For personal use only Create additional Undertake 5-batch analysis testing Successfully complete stage 3 trial Complete data package that helps us toxicology data – supports on scaled up manufacturing process work as part of Australia
Slide 17: Our Technology Targets Major Markets
2020 ANNUAL GENERAL MEETING OUR TECHNOLOGY TARGETS Our novel insecticide products have For personal use only potential application MAJOR MARKETS AND in large, global market segments estimated ADDRESSES SIGNIFICANT to represent a total Our technology addressable market provides a solution to address
Slide 18: Thank You
ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES BIO-GENE For personal use only TECHNOLOGY LIMITED 26 NOVEMBER 2020 Annual General Meeting THANK YOU
Bio-Gene Technology — Shareholder Meeting (November 2020) on 6ix